Revolution Medicines to Participate in Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Core Insights - Revolution Medicines, Inc. is a late-stage clinical oncology company focused on developing targeted therapies for RAS-addicted cancers [3] Company Overview - The company is developing a pipeline of RAS(ON) inhibitors aimed at suppressing various oncogenic variants of RAS proteins [3] - Current clinical development includes daraxonrasib (RMC-6236), a multi-selective inhibitor; elironrasib (RMC-6291), a G12C-selective inhibitor; zoldonrasib (RMC-9805), a G12D-selective inhibitor; and RMC-5127, a G12V-selective inhibitor [3] - Additional pipeline opportunities focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C) [3] Upcoming Events - Mark A. Goldsmith, M.D., Ph.D., CEO and Chairman of Revolution Medicines, will participate in a fireside chat at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 on February 11 at 9:30 a.m. ET [1]